Milmed Unico AB
Is an early-stage developer of medicinal probiotics with groundbreaking research providing global market. Our original product is a non-toxic product that has been tested by over 1200 people and no adverse side effects has been reported.
The Sapienza University, Europe’s largest university, have through in vitro-studies proven that Milmed is toxic free.
Milmed Unico AB has two patent protected treatment areas, allergic disorders and degenerative diseases plus one patent pending for inflammatory diseases. We are now preparing for Phase I studies and all our current treatment areas fit into one Phase I clinical trial.
The Company’s teams with many experienced experts are one complete homogeneous integrated group with control over the entire value chain from R&D, formulation and production to marketing and international sales. Together with the new chairman, Anders Milton, the Company is looking forward towards an exciting future.